Document Detail


Long-term (5 to 20 years) Evolution of nongrafted aplastic anemias. The Cooperative Group for the Study of Aplastic and Refractory Anemias.
MedLine Citation:
PMID:  2257296     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In the presence of aplastic anemia (AA), therapeutic choices should be determined while taking into account not only changes for immediate improvement, but also both the risks for late-occurring complications and the following quality of life. We report here data concerning a long-term clinical survey (5 to 18 years with a median of 12 years) including 156 nongrafted patients receiving androgen therapy; all patients were alive more than 5 years after diagnosis (40% of patients included at time of diagnosis in our multicentric analysis). Between the 5th and the 13th year follow-up, 21 patients died of various causes either related to AA or to its treatment: 12 of infection or hemorrhage secondary to pancytopenia (6 relapses and 6 that had never been improved; 2 with paroxysmal nocturnal hemoglobinuria [PNH]); 5 of leukemia; 1 of a non-Hodgkin's lymphoma; 2 of late side effects following transfusion (1 acquired immunodeficiency syndrome and 1 chronic B hepatitis); and a single case of myocardial infarction (the latter could possibly result of androgen therapy). Thirteen patients in total developed PNH (among which 10 had clinical symptoms including 2 deaths, and 3 exhibited only biologic abnormalities). Few long-term side effects of androgens could be noticed. Adult height was normal in patients treated during childhood and so was young women's fertility. No malignant hepatoma occurred. This survey allows the recording of late spontaneous hematologic improvement (between 5 and 10 years of evolution). This occurred in 50% of patients that had remained cytopenic 5 years after diagnosis. Although bone marrow stem cell concentration remained abnormal after 10 years of evolution. 85% of patients had a normal red blood cell count, 80% a normal polymorphonuclear count, and 66% a normal platelet count. All patients who did not show late complications had an excellent quality of life.
Authors:
Y Najean; O Haguenauer
Related Documents :
16434536 - The use of immunomodulators as an adjunct to antituberculous chemotherapy in non-respon...
19869756 - Studies in the blood cytology of the rabbit : v. consecutive lymphocyte and monocyte ob...
24482716 - Does adrenaline spraying over thyroidectomy area reduce bleeding?
10847256 - The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patient...
3970606 - Is routine postoperative nasogastric decompression really necessary?
19582386 - Comparative results of two techniques to treat stress urinary incontinence: synthetic t...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Blood     Volume:  76     ISSN:  0006-4971     ISO Abbreviation:  Blood     Publication Date:  1990 Dec 
Date Detail:
Created Date:  1991-01-29     Completed Date:  1991-01-29     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7603509     Medline TA:  Blood     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  2222-8     Citation Subset:  AIM; IM    
Affiliation:
Department of Nuclear Medicine and Hematology, Hôpital Saint-Louis, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Androgens / therapeutic use
Anemia, Aplastic / complications,  mortality,  therapy*
Cause of Death
Child
Female
Follow-Up Studies
Hemoglobinuria, Paroxysmal / etiology
Humans
Iatrogenic Disease
Immunosuppression
Leukemia / etiology
Male
Middle Aged
Myelodysplastic Syndromes / etiology
Pregnancy
Quality of Life
Survival Rate
Chemical
Reg. No./Substance:
0/Androgens

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Different effect of benzylacyclouridine on the toxic and therapeutic effects of azidothymidine in mi...
Next Document:  Species specificity of human interleukin-3 demonstrated by cloning and expression of the homologous ...